Expert review of respiratory medicine最新文献

COPD and the burden of multimorbidity: navigating the complexity. 慢性阻塞性肺病和多重疾病的负担：在复杂性中导航。

IF 2.7

Expert review of respiratory medicine Pub Date : 2025-10-07 DOI: 10.1080/17476348.2025.2569126

Maria Kallieri, Georgios Hillas, Konstantinos Bartziokas, Stelios Loukides, Dimitrios Toumpanakis

{"title":"COPD and the burden of multimorbidity: navigating the complexity.","authors":"Maria Kallieri, Georgios Hillas, Konstantinos Bartziokas, Stelios Loukides, Dimitrios Toumpanakis","doi":"10.1080/17476348.2025.2569126","DOIUrl":"https://doi.org/10.1080/17476348.2025.2569126","url":null,"abstract":"Introduction: Chronic obstructive pulmonary disease (COPD) is a chronic condition that affects millions of people worldwide. The majority of patients with COPD have multiple coexisting chronic diseases, such as cardiovascular diseases, osteoporosis, lung cancer, and metabolic syndrome, a phenomenon that is known as multimorbidity. The coexistence of these diseases with COPD complicates diagnosis, treatment, and prognosis.Areas covered: This review explores the underlining mechanisms that connect COPD and multimorbidity, such as shared risk factors and pathophysiological pathways. It also highlights the challenges in managing multimorbid patients and emphasizes the fact that the complexity of comorbidities may require a multidisciplinary approach in COPD management.Expert opinion: Managing COPD in the context of multimorbidity requires a multidisciplinary approach. This approach should combine pharmacological and non-pharmacological treatments for COPD, adhere to evidence-based guidelines for managing comorbidities, and target modifiable shared risk factors to improve overall patient outcomes.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"1-16"},"PeriodicalIF":2.7,"publicationDate":"2025-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145240622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advances in type 2-high asthma therapy: what remains missing? 2型高哮喘治疗的进展：还缺少什么？

IF 2.7

Expert review of respiratory medicine Pub Date : 2025-10-07 DOI: 10.1080/17476348.2025.2569844

Ahmad Z Al Meslamani, Anan S Jarab, Abdullah Elrefae

{"title":"Advances in type 2-high asthma therapy: what remains missing?","authors":"Ahmad Z Al Meslamani, Anan S Jarab, Abdullah Elrefae","doi":"10.1080/17476348.2025.2569844","DOIUrl":"10.1080/17476348.2025.2569844","url":null,"abstract":"Introduction: Type 2-high asthma (T2HA) accounts for most severe asthma morbidity and is driven by eosinophilic, IgE- and alarmin-mediated inflammation. Although five biologics are licensed, many patients remain symptomatic, corticosteroid-dependent or financially excluded.Areas covered: PubMed, Embase, Web of Science, Scopus, Cochrane Library, EconLit, ClinicalTrials.gov and WHO-ICTRP were searched (1 January 2005 - 30 June 2025). Evidence from randomized trials, economic evaluations and translational studies on biologics, small-molecule drugs, cell-based and microbiome-directed interventions was synthesized across four domains: late-stage attrition, ultra-long-acting biologic limitations, slow small-molecule progress, and cost - access barriers. Durability, pediatric data and OCS-sparing potential were also examined.Expert opinion: Phenotype-guided biologics have replaced corticosteroid escalation after two decades of research; nevertheless, plateaus in effectiveness, uncertain long-term safety profiles, and exorbitant costs persist. Future progress will depend on value-based pricing that facilitates global adoption, adaptive biomarker-anchored clinical trials, rational combination or bispecific therapeutics, and rigorous post-marketing surveillance of cell-based and microbiome-directed therapies. Delivering sustainable, equitable management of T2HA necessitates the coordination of scientific, regulatory, and economic mechanisms rather than focusing on increasingly narrow cytokine targets.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"1-14"},"PeriodicalIF":2.7,"publicationDate":"2025-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145202466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Multimorbidity in the modulator era: challenges of managing an ageing cystic fibrosis population. 调节剂时代的多病：管理老龄化囊性纤维化人群的挑战。

IF 2.7

Expert review of respiratory medicine Pub Date : 2025-10-05 DOI: 10.1080/17476348.2025.2568244

Alex Chan, Freddy Frost, Dilip Nazareth

{"title":"Multimorbidity in the modulator era: challenges of managing an ageing cystic fibrosis population.","authors":"Alex Chan, Freddy Frost, Dilip Nazareth","doi":"10.1080/17476348.2025.2568244","DOIUrl":"10.1080/17476348.2025.2568244","url":null,"abstract":"Introduction: Cystic Fibrosis (CF) is an autosomal recessive disorder caused by mutations in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene, leading to defective chloride ion transport and multisystem disease. The introduction of CFTR modulators, particularly elexacaftor/tezacaftor/ivacaftor (ETI), has significantly improved life expectancy and quality of life for people with CF (pwCF). As survival increases, an aging CF population faces different new challenges.Areas covered: This review aims to highlight emerging challenges and comorbidities in an aging CF population to ensure sustained benefits from recent therapeutic advancements. The review includes the discussion of the changes in lung function, nutrition, cardiometabolic diseases, malignancy risk and psychosocial health. A structured literature search was conducted using PubMed, focusing on articles published between 2000 and 2025, including recent clinical trials and international guidelines. National registry data has also been reviewed.Expert opinion: With CFTR modulators progress rapidly, the future focus should shift to refining and optimizing CF care. Standard practice should involve a multidisciplinary, proactive and preventative strategy to manage co-morbidities, ensuring the ultimate goal moving from simply extending pwCF's life to ensuring a high quality of life throughout their lifespan.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"1-11"},"PeriodicalIF":2.7,"publicationDate":"2025-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145188204","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Application of artificial intelligence for the detection of obstructive sleep apnea based on clinical and demographic data: a systematic review. 基于临床和人口统计数据的人工智能在阻塞性睡眠呼吸暂停检测中的应用：系统综述。

IF 2.7

Expert review of respiratory medicine Pub Date : 2025-10-05 DOI: 10.1080/17476348.2025.2567046

Manuel Casal-Guisande, Mar Mosteiro-Añón, María Torres-Durán, Alberto Comesaña-Campos, Alberto Fernández-Villar

{"title":"Application of artificial intelligence for the detection of obstructive sleep apnea based on clinical and demographic data: a systematic review.","authors":"Manuel Casal-Guisande, Mar Mosteiro-Añón, María Torres-Durán, Alberto Comesaña-Campos, Alberto Fernández-Villar","doi":"10.1080/17476348.2025.2567046","DOIUrl":"10.1080/17476348.2025.2567046","url":null,"abstract":"Introduction: Artificial intelligence (AI) has shown promise in enhancing the detection and stratification of obstructive sleep apnea (OSA) using clinical and demographic data. This systematic review assessed the effectiveness of AI models, methodological quality, and future research needs.Methods: Following PRISMA guidelines, a systematic search of PubMed (2014-2024) identified studies applying AI to detect or stratify OSA using clinical/demographic data, validated against polysomnography or cardiorespiratory polygraphy, and reporting performance metrics such as the area under the curve (AUC). Studies primarily based on wearable devices were excluded. Methodological quality and risk of bias were evaluated using the PROBAST tool.Results: Of 447 records, 26 met inclusion criteria. Common algorithms included decision trees, support vector machines, and neural networks, frequently using variables such as age, BMI, neck circumference, and comorbidities. AUC values ranged from 0.62 to 0.93, with most exceeding 0.80. Research output increased substantially between 2021 and 2024. Methodological heterogeneity and limited external validation hindered comparability. Exclusion of incomplete cases was a recurrent issue.Conclusions: AI models show potential for improving OSA detection, but methodological limitations restrict generalizability. Future studies should prioritize external validation, diverse populations, and adherence to standardized reporting frameworks to enable clinical translation.Protocol registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251025868 identifier is CRD420251025868.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"1-18"},"PeriodicalIF":2.7,"publicationDate":"2025-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145139820","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

High burden of severe and very severe undernutrition among adults with tuberculosis: findings from a state wide operational research in Chhattisgarh, India. 成人结核病患者严重和极严重营养不良的高负担：来自印度恰蒂斯加尔邦一项全国性业务研究的结果。

IF 2.7

Expert review of respiratory medicine Pub Date : 2025-10-05 DOI: 10.1080/17476348.2025.2569845

Vishnu Gupta, Chetanya Malik, Kalpita Shringarpure, Himanshu A Gupte, Hemant D Shewade, Khemraj Sonwani, Vikash Ranjan Keshri

{"title":"High burden of severe and very severe undernutrition among adults with tuberculosis: findings from a state wide operational research in Chhattisgarh, India.","authors":"Vishnu Gupta, Chetanya Malik, Kalpita Shringarpure, Himanshu A Gupte, Hemant D Shewade, Khemraj Sonwani, Vikash Ranjan Keshri","doi":"10.1080/17476348.2025.2569845","DOIUrl":"10.1080/17476348.2025.2569845","url":null,"abstract":"Background: Undernutrition drives the TB epidemic in India with 4-5 times higher mortality among adults with severe/very severe undernutrition. We assessed proportion of severe/very severe undernutrition among adults with TB and timeliness in receiving monetary support for nutrition (Direct benefit transfer-DBT) and food baskets.Research design and methods: This analytical cross-sectional study conducted in Chhattisgarh, tribal Indian state, utilized program data of adults with TB notified in public facilities under the National TB Elimination Program from April-June 2024. Body Mass Index (BMI) was categorized for nutritional status and equity in distribution of DBT and foodbaskets was evaluated using frequency, proportions, and Chi-square for trend.Results: Of 6568 adults with TB, BMI was calculated for 6397 (97%). Proportion of severe and very severe undernutrition was 22% and 13% respectively. First DBT instalment was received by 81%, with 29% receiving it within two months; 21% received foodbaskets, with similar coverage across all undernutrition categories (p > 0.05), reflecting inequity.Conclusions: There is a high burden of severe/very severe undernutrition among TB patients. Similar DBT and food basket coverage among those with severe/very severe undernutrition and other TB patients indicates inequity in distribution. Undernutrition-basedindicators and linkage of DBT and food baskets should be prioritized.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"1-7"},"PeriodicalIF":2.7,"publicationDate":"2025-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145214754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Do we know about respiratory syncytial virus in Türkiye? 我们知道呼吸道合胞病毒在<s:1>基耶病毒？

IF 2.7

Expert review of respiratory medicine Pub Date : 2025-10-04 DOI: 10.1080/17476348.2025.2569125

Dilşah Başkol Elik, Gökhan Vatansever, Selin Ece Taşbakan, Serdal Ateş, Hüsnü Pullukçu, Meltem Taşbakan, İftihar Köksal

{"title":"Do we know about respiratory syncytial virus in Türkiye?","authors":"Dilşah Başkol Elik, Gökhan Vatansever, Selin Ece Taşbakan, Serdal Ateş, Hüsnü Pullukçu, Meltem Taşbakan, İftihar Köksal","doi":"10.1080/17476348.2025.2569125","DOIUrl":"10.1080/17476348.2025.2569125","url":null,"abstract":"Background: Respiratory Syncytial Virus (RSV) is a major cause of severe respiratory illness in infants, older adults, and immunocompromised individuals. However, data on physicians' knowledge and attitudes toward RSV and its prevention in Türkiye are limited. The aim of this study was to evaluate the knowledge and attitudes of physicians in Türkiye about RSV.Research design and methods: A cross-sectional online survey was conducted among physicians in Türkiye between October and November 2024.Results: A total of 1270 physicians (median age: 35; 62.44% female) participated, 30.5% of whom specialized in Infectious Diseases (ID). While 43.54% correctly identified RSV symptoms, only 15.9% recognized high-risk groups, and 49.7% were familiar with associated clinical conditions. ID specialists had significantly greater knowledge of symptoms (p = 0.015) and complications (p < 0.001) compared to other physicians. Overall, 51.57% perceived the national RSV burden as high. However, only 40.31% were aware of prevention tools. Although 51.88% knew about FDA-approved RSV vaccines, just 21.54% knew they were not yet available in Türkiye. Among vaccine-aware participants, most would recommend it to elderly (85.28%), while fewer supported maternal vaccination (58.87%).Conclusions: These findings reveal that despite higher knowledge among ID physicians, overall awareness of RSV and its prevention is inadequate.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"1-8"},"PeriodicalIF":2.7,"publicationDate":"2025-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145214577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impairment of neural mechanosensitivity in the Long COVID haulers. COVID - 19长途运输车辆神经力学敏感性损伤。

IF 2.7

Expert review of respiratory medicine Pub Date : 2025-10-02 DOI: 10.1080/17476348.2025.2568243

Andrés Calvache-Mateo, Alberto Rodríguez-López, Alba Navas-Otero, Javier Martín Núñez, Alejandro Heredia-Ciuró, Laura López-López, Marie Carmen Valenza

{"title":"Impairment of neural mechanosensitivity in the Long COVID haulers.","authors":"Andrés Calvache-Mateo, Alberto Rodríguez-López, Alba Navas-Otero, Javier Martín Núñez, Alejandro Heredia-Ciuró, Laura López-López, Marie Carmen Valenza","doi":"10.1080/17476348.2025.2568243","DOIUrl":"10.1080/17476348.2025.2568243","url":null,"abstract":"Background: The aim of this study was to evaluate and characterize the alteration in mechanosensitivity in Long COVID haulers as well as its impact on patients' functionality and quality of life.Research design and methods: In this study there were two groups: a group of Long COVID haulers and a group of healthy controls matched for age and sex. The mechanosensitivity clinical profile and peripheral nerve mechanosensitivity were evaluated. The mechanosensitivity clinical profile included the functionality and quality of life (World Health Organization Disability Assessment Schedule 2.0, Patient-Reported Outcomes Measurement Information System, EuroQol-5 Dimensions) and neural mechanosensitivity (Leeds Assessment of Neuropathic Symptoms and Signs). The peripheral nerve mechanosensitivity included neurodynamic tests (median, radial, ulnar, slump test and straight leg raise).Results: A total of 64 patients were included in the study (Long COVID haulers group n = 33, healthy controls group n = 31). Long COVID haulers group obtained significantly worse results in functionality (p < 0.001), quality of life (p < 0.001), neural mechanosensitivity (p < 0.001) and peripheral nerve mechanosensitivity (p < 0.001).Conclusions: Long COVID haulers have significant alterations in neural mechanosensitivity, contributing to a greater degree of functional impairment and poorer quality of life.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"1-7"},"PeriodicalIF":2.7,"publicationDate":"2025-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145180800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effect of fixed-dose tiotropium/olodaterol combined therapy on exercise-related outcome measures in individuals with chronic obstructive pulmonary disease: a systematic review and meta-analysis. 固定剂量噻托溴铵/奥替特罗联合治疗对慢性阻塞性肺疾病患者运动相关结局指标的影响：一项系统综述和荟萃分析

IF 2.7

Expert review of respiratory medicine Pub Date : 2025-10-01 Epub Date: 2025-06-25 DOI: 10.1080/17476348.2025.2522754

Sanaa A Alsubheen, Myanca Rodrigues, Kristian Thorlund

{"title":"Effect of fixed-dose tiotropium/olodaterol combined therapy on exercise-related outcome measures in individuals with chronic obstructive pulmonary disease: a systematic review and meta-analysis.","authors":"Sanaa A Alsubheen, Myanca Rodrigues, Kristian Thorlund","doi":"10.1080/17476348.2025.2522754","DOIUrl":"10.1080/17476348.2025.2522754","url":null,"abstract":"Introduction/objectives: This systematic review aimed to summarize the evidence on the effect of the fixed-dose combination of tiotropium/olodaterol (Tio/Olo 5/5 μg FDC) on exercise-related outcome measures.Methods: We included randomized clinical trials (RCTs) from four databases that investigated the effectiveness of Tio/Olo 5/5 μg FDC on exercise tolerance, breathlessness, lung function, and physical activity from inception to October 2024.Results: Findings from eight RCTs indicated that Tio/Olo 5/5 μg FDC was superior to Tio 5 μg or placebo for the following outcomes: exercise tolerance [Tio 5 μg: 3 RCTs, mean difference (MD) = 16.6 m, 95% CI: 5.2-28.1, p < 0.001], exercise endurance time [Placebo: 2 RCTs, SMD = 0.29, 95% CI: 0.19-0.39, p = p < 0.001], inspiratory capacity [Tio 5 μg: 3 RCTs, MD = 0.13 L, 95% CI: 0.07-0.19, p < 0.001], and forced expiratory volume in 1 second (FEV1) [Tio 5 μg: 4 RCTs, MD = 0.12 L, 95% CI: 0.11-0.14, p < 0.001; Placebo: 2 RCTs, MD = 0.33 L, 95% CI: 0.3-0.35, p < 0.001], with no effect on physical activity levels.Conclusion: Tio/Olo 5/5 μg FDC compared to Tio 5 μg or placebo may improve exercise tolerance and lung function, but not physical activity levels in COPD.Protocol registration: The systematic review protocol is registered on PROSPERO (International Prospective Register of Systematic Reviews): number CRD42024598553.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"1081-1092"},"PeriodicalIF":2.7,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144328219","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Social determinants of health, early diagnosis, and ageing in patients with interstitial lung disease. 间质性肺病患者健康、早期诊断和老龄化的社会决定因素。

IF 2.7

Expert review of respiratory medicine Pub Date : 2025-10-01 Epub Date: 2025-06-24 DOI: 10.1080/17476348.2025.2523501

Abebaw Mengistu Yohannes

{"title":"Social determinants of health, early diagnosis, and ageing in patients with interstitial lung disease.","authors":"Abebaw Mengistu Yohannes","doi":"10.1080/17476348.2025.2523501","DOIUrl":"10.1080/17476348.2025.2523501","url":null,"abstract":"Introduction: Interstitial lung disease (ILD) is a heterogenous, chronic, progressive lung disease characterized by thickening and scar fibrosis of lung tissue, interstitial alveolar damage, severe airways limitations, and impaired gas exchange which leads to breathlessness and fatigue.Areas covered: Based on the available literature, only a few studies were identified that examined social determinants of health (SDOH) in the early diagnosis of ILD. The findings highlighted that those patients from low socioeconomic status and highly deprived communities had greater barriers in accessing healthcare, delayed diagnosis of ILD, and receiving lung transplant surgery. We discuss the challenges encountered by both patients and physicians for early diagnosis and suggest potential strategies to identify and accelerate treatment of patients with ILD.Expert opinion: SDOH exerts substantial burdens upon patients with ILD. Delays in the diagnosis of ILD are associated with increased disease burden, elevated stress, anxiety, depression, frequent acute exacerbations, and premature death. SDOH heavily affect patients from low socioeconomic status and disadvantaged communities. Innovative strategies are required to address healthcare disparities on early diagnosis and treatment of ILD. Thus, patients with ILD and with identified SDOH may need dedicated additional support to improve care and focused areas for future research.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"1037-1042"},"PeriodicalIF":2.7,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144328221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The safety of asthma treatment and management strategies in pregnancy. 妊娠期哮喘治疗的安全性及管理策略。

IF 2.7

Expert review of respiratory medicine Pub Date : 2025-10-01 Epub Date: 2025-06-24 DOI: 10.1080/17476348.2025.2522757

Andrea E Davis, Michael E Wechsler, Jennifer A Namazy, Michael Schatz

{"title":"The safety of asthma treatment and management strategies in pregnancy.","authors":"Andrea E Davis, Michael E Wechsler, Jennifer A Namazy, Michael Schatz","doi":"10.1080/17476348.2025.2522757","DOIUrl":"10.1080/17476348.2025.2522757","url":null,"abstract":"Introduction: Poor asthma control in pregnancy is associated with worse maternal and fetal outcomes. Despite this, many patients and providers opt not to continue treatment in pregnancy, largely due to fear of teratogenicity. The goal of this review is to inform providers about the safety of asthma medication in pregnancy as well as strategies for encouraging patients to adhere to these medications.Areas covered: To prepare this narrative review article, we performed a database search using PubMed, Cochrane Library, Embase, Web of Science, and Google Scholar to obtain a broad range of clinical studies, systematic reviews, and meta-analyses related to asthma management during pregnancy. Search terms included asthma, pregnan*, treat*, therap*, manage*, and comorbid* with Boolean operators used to refine the search. Studies were limited to those published in the English language from 2000 to 2025.Expert opinion: Most classes of medications used to treat asthma have reassuring safety data for use in pregnancy. Additional data are needed to assess the use of biologics in pregnancy, which have become a cornerstone of management for non-pregnant patients with severe asthma. Routine visits with providers and identifying treatable traits can also improve outcomes in these patients.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"1043-1054"},"PeriodicalIF":2.7,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144334728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0